early Breast Cancer

ENG

KATHERINE, PHERGain (ASCO23), KEYNOTE-522, ALEXANDRA/IMpassion030, KEYNOTE-756 (ESMO&SABCS), CheckMate-7FL

SABCS 2023

YiR in EBC #1: New data in HER2+ and Immunotherapy in…

M. Untch, H. Rugo, E. de Azambuja, C. Criscitiello, E. Senkus-Konefka, W. Janni

ENG

SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304, Oxford analyses ASCO23, monarchE, NATALEE, POSITIVE (SABCS22 &23)

SABCS 2023

YiR in EBC #2: De-escalating therapy in locoregional…

M. Untch, H. Rugo, E. de Azambuja, C. Criscitiello, E. Senkus-Konefka, W. Janni

advanced Breast Cancer

ENG

BEGONIA, SAFIR02-Breast, HER2CLIMB02, KATHERINE, COMPASS, DESTINY-Breast -01, -02, -03, TULIP, monarcHER

SABCS 2023

YiR in ABC #1: Exciting new data for first line mTNBC,…

V. Müller, R. Dent, K. Gelmon, A. Gennari, V. Diéras, S. Tolaney

ENG

SONIA, monarch3, PARSIFAL-long, INAVO120, RIGHT-Choice, PALMIRA, EMERALD, CAPItello291

SABCS 2023

YiR in ABC #2: New data on treatment in metastatic HR+…

V. Guarneri, V. Müller, R. Dent, K. Gelmon, A. Gennari, V. Diéras, S. Tolaney, C. Criscitiello

ENG

DESTINY-Breast 04, TROPiCS-02, TROPION-Breast01

SABCS 2023

YiR in ABC #3: Exciting new data on ADCs in HR+ breast…

V. Guarneri, V. Müller, R. Dent, K. Gelmon, A. Gennari, V. Diéras, S. Tolaney, C. Criscitiello

EBC HR+ HER2-

ENG

ADAPTcycle

SABCS 2023

ADAPTcycle - endocrine response

Nadia Harbeck, MD, PhD

ENG

KEYNOTE-756

SABCS 2023

KEYNOTE-756 - Subgroup analysis

Nadia Harbeck, MD, PhD

ENG

monarchE

SABCS 2023

cTDNA analyses in monarchE

Eva M. Ciruelos, MD, PhD

ENG

NATALEE

SABCS 2023

Final iDSF analysis in NATALEE

Peter Fasching, MD

ENG

CheckMate756, KEYNOTE-756, POSITIVE

SABCS 2023

SABCS23 highlights in early breast cancer

Giuseppe Curigliano, MD, PhD

ENG

NATALEE

SABCS 2023

An enrichment of therapy options in the endocrine…

Wolfang Janni, MD

ENG

CheckMate 7FL

SABCS 2023

CheckMate7FL - Biomarker

Nadia Harbeck, MD, PhD

ENG

KEYNOTE-756

SABCS 2023

Prediction of pCR in KEYNOTE-756

Peter Fasching, MD

ENG

CheckMate 7FL, KEYNOTE-756

SABCS 2023

Hope with CPI for luminal breast cancer

Michael Untch, MD

EBC HER2+

ENG

KATHERINE

SABCS 2023

T-DM1 in post-neoadjuvant therapy now also with…

Wolfang Janni, MD

ENG

KATHERINE

SABCS 2023

KATHERINE: OS improvement in HER2+ eBC

Véronique Diéras, MD

ENG

SURVIVE, SURVIVE HERoes

SABCS 2023

Change in the standard of follow-up care?

Wolfang Janni, MD

EBC TNBC

ENG

ALEXANDRA/IMpassion030

SABCS 2023

Immunotherapy for early TNBC must be neoadjuvant

Diana Lüftner, MD

EBC Pregnancy and Fertility

ENG

SABCS 2023

Pregnancy after BC is safe - also in germline BRCA+ pts

Valentina Guarneri, MD, PhD

ENG

POSITIVE

SABCS 2023

Importance of the onco-fertility discussion

Evandro de Azambuja, MD

ENG

POSITIVE

SABCS 2023

Pregnancy despite endocrine therapy in HR+ breast…

Wolfang Janni, MD

EBC Other

ENG

SABCS 2023

Anthtracyclines in EBC: to give or not to give?

Evandro de Azambuja, MD

EBC multilanguage

ITA

SABCS 2023

Gravidanza dopo la diagnosi di carcinoma mammario è…

Valentina Guarneri, MD, PhD

ITA

CheckMate756, KEYNOTE-756, POSITIVE

SABCS 2023

SABCS23 evidenzia il cancro al mammario in fase precoce

Giuseppe Curigliano, MD, PhD

POR

POSITIVE

SABCS 2023

Importância da discussão sobre onco-fertilidade

Evandro de Azambuja, MD

ESP

monarchE

SABCS 2023

Análisis de cTDNA en monarchE

Eva M. Ciruelos, MD, PhD

FRA

KATHERINE

SABCS 2023

KATHERINE : amélioration de la survie globale dans le…

Véronique Diéras, MD

ABC HR+ HER2-

ENG

DESTINY-Breast08

SABCS 2023

T-DXd + endocrine therapy interesting for HR+ HER2low…

Andreas Schneeweiss, MD

USA

MONARCH 3

SABCS 2023

Does abemciclib lead to improved OS survival in the 1st…

Sara Tolaney, MD

ENG

MONARCH 3

SABCS 2023

SABCS23 highlights in metastatic breast cancer

Giuseppe Curigliano, MD, PhD

ENG

FOENIX-MBC2 study

SABCS 2023

Fulvestrant + futibatinib interesting for FGFR1…

Andreas Schneeweiss, MD

ENG

MONARCH 3

SABCS 2023

Final OS analysis in MONARCH 3

Peter Fasching, MD

ENG

TROPION-Breast01

SABCS 2023

Dato-Dxd achieves PFS

Eva M. Ciruelos, MD, PhD

ENG

CAPItello-292

SABCS 2023

Capiversatib + Palbociclib + Fulvestrant in HR+ HER2-…

Barbara Pistilli, MD

ENG

MONARCH 3

SABCS 2023

Is OS important?

Karen Gelmon, MD

ENG

MONARCH 3

SACBS 2023

MONARCH 3 shows clinically relevant OS-benefit without…

Diana Lüftner, MD

ENG

PARSIFAL-LONG

SABCS 2023

Long follow-up of CDK4/6i

Karen Gelmon, MD

USA

INAVO120

SABCS 2023

Promising data for the PIK3CA-inhibitor inavolisib

Hope Rugo, MD

ENG

PARSIFAL-LONG

SABCS 2023

OS benefit with fulvestrant/letrozole + palbocilib is…

Javier Cortés, MD, PhD

ENG

INAVO120

SASBCS 2023

PIK3CA-inhibitor: positive results in Phase III

Véronique Diéras, MD

ENG

PARSIFAL-LONG

SABCS 2023

Letrozole + palbo as effective as fulvestrant + palbo

Andreas Schneeweiss, MD

ABC HER2+

ENG

HER2CLIMB-02

SABCS 2023

Tucatinib + T-DM1 interesting for specific patients

Diana Lüftner, MD

ENG

AVIATOR/TBCRC045

SABCS 2023

Avelumab appears to be effective in HER2+ mBC

Andreas Schneeweiss, MD

USA

HER2CLIMB-02

SABCS 2023

New potential backbone for tucatinib in mHER2+ BC

Sara Tolaney, MD

ENG

HER2CLIMB-02

SABCS 2023

Tucatinib + T-DM1: Possible role in the contemporary…

Valentina Guarneri, MD, PhD

ENG

HER2CLIMB-02

SABCS 2023

Efficacy of tucatinib confirmed, but unclear for which…

Elzbieta Senkus-Konefka, MD, PhD

ENG

ASPIRE

SABCS 2023

Effective, chemo-free combination for triple-positive…

Andreas Schneeweiss, MD

ABC TNBC

USA

KEYLYNK-009

SABCS 2023

KEYLYNK-009: Pembrolizumab + olaparib a well-tolerated…

Hope Rugo, MD

ABC Loco-regional recurrence and physical activity

ENG

PREFERABLE-EFFECT

SABCS 2023

Metastatic patients can and must exercise

Diana Lüftner, MD

ENG

SENOMAC

SABCS 2023

Axillary surgery de-escalation

Eva M. Ciruelos, MD, PhD

ENG

ICARO

SABCS 2023

Isolated tumor cells in the sentinel lymph node - does…

Wolfang Janni, MD

ENG

SENOMAC

SABCS 2023

Positive sentinel lymph node after mastectomy

Wolfang Janni, MD

ENG

NRG Oncology/NSABP B-51/RTOG 1304

SABCS 2023

Axillary radiotherapy can be omitted in T3N1 BC pts

Alessandra Gennari, MD

SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304

SABCS 2023

Rethinking management of the axilla

Elzbieta Senkus-Konefka, MD, PhD

ENG

PREFERABLE-EFFECT

SABCS 2023

Physical acitivity improves QoL in advanced BC

Alessandra Gennari, MD

ABC Other

ADAPTcycle

SABCS 2023

Poster insights: PO4-01-10 ADAPTcycle

Daniel Kates-Harbeck

ENG

OLAnzaPiNE

SABCS 2023

Low-dose olanzapine more favorable in the prophylaxis…

Andreas Schneeweiss, MD

ABC multilanguage

ITA

MONARCH 3

SABCS 2023

SABCS23 evidenzia nel cancro al mammario metastatico

Giuseppe Curigliano, MD, PhD

ESP

SENOMAC

SABCS 2023

Desescalada de cirugía axilar

Eva M. Ciruelos, MD, PhD

POL

HER2CLIMB-02

SABCS 2023

Tukatynib skuteczny, ale czy umiemy określić jego…

Elzbieta Senkus-Konefka, MD, PhD

ESP

PARSIFAL-LONG

SABCS 2023

La supervivencia obtenida con palbociclib y…

Javier Cortés, MD, PhD

FRA

INAVO120

SABCS 2023

Inhibiteur de PIK3CA: résultats positifs en phase III

Véronique Diéras, MD

ITA

PREFERABLE-EFFECT

SABCS 2023

L'attività fisica migliora la qualità di vita nel…

Alessandra Gennari, MD, PhD

ITA

NRG Oncology/NSABP B-51/RTOG 1304

SABCS 2023

La radioterapia ascellare può essere omessa nelle…

Alessandra Gennari, MD, PhD

ESP

TROPION-Breast01

SABCS 2023

Dato-Dxd consigue PFS

Eva M. Ciruelos, MD, PhD

ITA

CAPItello-292

SABCS 2023

Capiversatib + Palbociclib + Fulvestrant nel carcinoma…

Barbara Pistilli, MD

POL

SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304

SABCS 2023

Duże zmiany w leczeniu pachy

Elzbieta Snkus-Konefka, MD, PhD

ITA

HER2CLIMB-02

SABCS 2023

Tucatinib + T-DM1: Possibile un ruolo nello scenario…

Valentina Guarneri, MD, PhD

FRA

CAPItello-292

SABCS 2023

Capiversatib + Palbociclib + Fulvestrant dans le cancer…

Barbara Pistilli, MD

General Session 1

ENG

HER2CLIMB-02

SABCS 2023

New and good therapy options for HER2+ patients

N. Harbeck, G. Curigliano, V. Diéras, K. Gelmon, S. Tolaney, A. Schneeweiss

ENG

MONARCH 3

SABCS 2023

No significant OS - but what is the impact on clincial…

N. Harbeck, G. Curigliano, V. Diéras, K. Gelmon, S. Tolaney, A. Schneeweiss

ENG

CheckMate-7FL, Keynote-756, ALEXANDRA/IMpassio030, KEYLYNK-009

SABCS 2023

Immunotherapy and combination therapies for HR+/HER2-…

N. Harbeck, G. Curigliano, V. Diéras, K. Gelmon, S. Tolaney, A. Schneeweiss

General Session 2

ENG

POSITIVE

SABCS 2023

Pregnancy is safe after endocrine therapy

M. Untch, W. Janni, E. Senkus-Konefka, V. Guarneri, H. Rugo, A. Gennari

ENG

OPBC05/EUBREAST-14R/ICARO, SENOMAC

SABCS 2023

DE-escalation of the axillary interverntion after…

M. Untch, W. Janni, E. Senkus, R. Dent, Hope, A. Gennari

ENG

NRG Oncology, NSABP B-51, RTOG 1304

SABCS 2023

De-escalation of radiotherapy after neoadjuvant therapy

D. Lüftner, E. Senkus-Konefka, H. Rugo, M. Untch, B. Pistilli, P. Fasching

ENG

TROPION-Breast01

SABCS 2023

Good balance between benefits and side effect - but not…

M. Untch, W. Janni, R. Dent, V. Guarneri, H. Rugo, A. Gennari

General Session 3

ENG

Katherine

SABCS 2023

OS and final iDFS data - confirming data but risk and…

D. Lüftner, E. Senkus-Konefka, H. Rugo, E. de Azambuja, B. Pistilli, M. Untch

ENG

NATALEE, monarchE

SABCS 2023

Final iDFS data - is everything clear yet?

D. Lüftner, E. Senkus-Konefka, H. Rugo, E. de Azambuja, B. Pistilli, P. Fasching

ENG

INAVO120

SABCS 2023

PI3K inihbitor Inavolisib shows improved PFS - one step…

D. Lüftner, E. Senkus-Konefka, H. Rugo, E. de Azambuja, B. Pistilli, P. Fasching